
    
      The primary objective of this study is to:

      â€¢ To determine the incidence of grade 3 to 5 non-hematologic toxicity of high-dose cytarabine
      (HiDAC) for AML consolidation administered in an outpatient setting.

      The secondary objectives of this study are to:

        -  To determine cost effectiveness of outpatient HiDAC consolidation versus the standard of
           care inpatient HiDAC consolidation.

        -  Evaluate patient quality of life (QOL) with this outpatient regimen in comparison to
           that with the standard inpatient regimen.
    
  